Theoretically, the detection of CTC in peripheral blood of a prostate cancer patient would imply that prognosis is worse than in a CTC-negative person, also after adjustment for potential confounders, such as age, performance status, serum PSA, and others. The gene discussed is KLK3; the disease is prostate cancer.